Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marta Paoli
Observed names:
M. Paoli,
Paoli, Marta
Institutions:
Politecnico di Torino,
University of Trento,
Azienda Usl Toscana Centro,
Hospital of Prato,
University of Florence
Observed institutions:
Politecnico di Torino,
University of Trento,
Sheba Medical Center,
Azienda Usl Toscana Centro,
Hospital of Prato,
University of Florence
show all 6
ORCID:
0000-0001-5047-5571
Observed ORCID:
0000-0001-5047-5571
OpenAlex ID:
A5041615182
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
2021
·
Philippe Aftimos
, Mafalda Oliveira
, et al.
·
Cancer Discovery
·
197
PDF
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
2022
·
Ilenia Migliaccio
, Marta Paoli
, et al.
·
npj Breast Cancer
·
18
PDF
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer
2025
·
Riccardo Scandino
, Agostina Nardone
, et al.
·
npj Breast Cancer
·
9
Germline determinants of aberrant signaling pathways in cancer
2024
·
Davide Dalfovo
, Riccardo Scandino
, et al.
·
npj Precision Oncology
·
5
PDF
MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples
2023
·
Dario Romagnoli
, Agostina Nardone
, et al.
·
Briefings in Bioinformatics
·
5
PDF
Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01.
2023
·
Florentine Hilbers
, David Venet
, et al.
·
Journal of Clinical Oncology
·
4
PDF
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2025
·
Paolo Manca
, Marta Paoli
, et al.
·
Clinical Cancer Research
·
3
T2T-CHM13 reference genome reduces mapping bias and enhances alignment accuracy at disease-associated variants
2026
·
Ilaria Cherchi
, Francesco Orlando
, et al.
·
iScience
·
2
PDF
A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing
2026
·
Marta Paoli
, Francesca Galardi
, et al.
·
Genome Medicine
·
2
A Standalone Immersive VR System for Upper Limb Stroke Rehabilitation
2026
·
Marta Paoli
, Domiziana Falaschi
, et al.
·
IEEE Smart World Congress (SWC)
The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors
2026
·
Ilenia Migliaccio
, Marta Paoli
, et al.
·
The Breast
Supplementary Table S1 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Figure S1 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Supplementary Table S8 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Supplementary Table S2 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Figure S7 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Figure S2 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Figure S6 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Figure S3 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Figure S5 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Supplementary Tables from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Figure S4 from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Data from ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2026
·
Paolo Manca
, Marta Paoli
, et al.
Abstract PD2-07: Multi-omics characteristics of ER+/HER2- breast cancer switching to metastatic non-luminal subtype: findings from the AURORA study (BIG14-01)
2026
·
M. Benelli
, A. Guerrero-Zotano
, et al.
·
Clinical Cancer Research
Assessing the Confidence and Competency of Nurses in the Management of Pharmacotherapy in Older Patients: a Cross-sectional Study
2026
·
CarmenMaria Vitiello
, Rita Manuela Bruno
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
36
Citation count:
247
H-index:
5
I10-index:
2
Year
Topic
Type